UY34201A - Compuestos de azaindol y métodos para el tratamiento de vih. - Google Patents
Compuestos de azaindol y métodos para el tratamiento de vih.Info
- Publication number
- UY34201A UY34201A UY0001034201A UY34201A UY34201A UY 34201 A UY34201 A UY 34201A UY 0001034201 A UY0001034201 A UY 0001034201A UY 34201 A UY34201 A UY 34201A UY 34201 A UY34201 A UY 34201A
- Authority
- UY
- Uruguay
- Prior art keywords
- azaindol
- compounds
- methods
- hiv treatment
- hiv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan compuestos y sales farmacéuticamente aceptables de los mismos, sus composiciones farmacéuticas, sus métodos de preparación, y su uso para el tratamiento de infecciones virales mediadas por un miembro de la familia de retrovirus, tal como el virus de inmunodeficiencia humana (HIV).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161508197P | 2011-07-15 | 2011-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY34201A true UY34201A (es) | 2013-02-28 |
Family
ID=47519251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001034201A UY34201A (es) | 2011-07-15 | 2012-07-13 | Compuestos de azaindol y métodos para el tratamiento de vih. |
Country Status (8)
Country | Link |
---|---|
US (1) | US8609653B2 (es) |
EP (1) | EP2731436B1 (es) |
JP (1) | JP6055468B2 (es) |
AR (1) | AR087184A1 (es) |
ES (1) | ES2624984T3 (es) |
TW (1) | TW201317237A (es) |
UY (1) | UY34201A (es) |
WO (1) | WO2013012649A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2640729B1 (en) | 2010-11-15 | 2016-12-21 | VIIV Healthcare UK Limited | Inhibitors of hiv replication |
EP2781519B1 (en) * | 2011-11-15 | 2019-10-30 | ST Pharm Co., Ltd. | Novel antiviral pyrrolopyridine derivative and a production method for same |
PT2877468T (pt) | 2012-07-12 | 2017-11-21 | Viiv Healthcare Uk Ltd | Compostos e métodos para o tratamento de vih |
TW201441197A (zh) | 2013-01-31 | 2014-11-01 | Shionogi & Co | Hiv複製抑制劑 |
EP2821082A1 (en) | 2013-07-05 | 2015-01-07 | Laboratoire Biodim | Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use |
PT3105236T (pt) | 2014-02-12 | 2017-12-22 | Viiv Healthcare Uk (No 5) Ltd | Macrociclos de benzotiazole como inibidores da replicação do vírus da imunodeficiência humana |
US9409922B2 (en) | 2014-02-18 | 2016-08-09 | Bristol-Myers Squibb Company | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication |
EP3116879A1 (en) | 2014-02-18 | 2017-01-18 | VIIV Healthcare UK (No.5) Limited | Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
US9834566B2 (en) | 2014-02-18 | 2017-12-05 | VIIV Healthcare UK (No.5) Limited | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
US9273067B2 (en) | 2014-02-19 | 2016-03-01 | Bristol-Myers Squibb Company | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
CN103864661A (zh) * | 2014-04-01 | 2014-06-18 | 湖南华腾制药有限公司 | 一种2-氨基-3-氰基吡咯衍生物的合成工艺 |
EP3144311A4 (en) | 2014-05-16 | 2018-01-03 | Shionogi & Co., Ltd. | Tricyclic heterocyclic derivative having hiv replication-inhibiting effect |
KR101592370B1 (ko) * | 2014-06-09 | 2016-02-11 | 한국화학연구원 | 신규한 피롤로피리딘 유도체 및 이의 hiv 저해제로서의 용도 |
US10112899B2 (en) * | 2014-07-08 | 2018-10-30 | Viiv Healthcare Uk Limited | Isoindoline derivatives for use in the treatment of a viral infection |
PT3172200T (pt) | 2014-07-22 | 2019-01-17 | Viiv Healthcare Uk Ltd | Derivados de isoindolinona úteis como agentes antivirais |
JP6614585B2 (ja) | 2015-05-29 | 2019-12-04 | 塩野義製薬株式会社 | Hiv複製阻害作用を有する含窒素3環性誘導体 |
JP2018520162A (ja) * | 2015-07-06 | 2018-07-26 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−3−イル酢酸誘導体 |
KR20180025926A (ko) * | 2015-07-08 | 2018-03-09 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제로서의 피리딘-3-일 아세트산 유도체 |
JP6898914B2 (ja) | 2015-07-20 | 2021-07-07 | ジェンザイム・コーポレーション | コロニー刺激因子−1受容体(csf−1r)阻害剤 |
WO2018020357A1 (en) | 2016-07-25 | 2018-02-01 | Viiv Healthcare Uk Limited | Indoline derivatives |
MX2019011220A (es) * | 2017-03-24 | 2019-11-01 | St Pharm Co Ltd | Compuesto de pirrolopiridina novedoso, metodo de preparacion del mismo y uso del mismo. |
TWI748194B (zh) | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Fxr有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
KR20220023187A (ko) * | 2020-08-20 | 2022-03-02 | 에스티팜 주식회사 | 피롤로피리딘 유도체 및 이들의 용도 |
EP4267573A1 (en) | 2020-12-23 | 2023-11-01 | Genzyme Corporation | Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors |
US20240317737A1 (en) * | 2021-01-11 | 2024-09-26 | St Pharm Co., Ltd. | Pyrrolopyridine derivative preparation method |
CN113173884B (zh) * | 2021-05-06 | 2023-08-15 | 陕西师范大学 | 二氯二茂钛催化汉斯酯1,4-二氢吡啶类化合物合成吡啶及其衍生物的方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
EP1196384A4 (en) * | 1999-06-25 | 2002-10-23 | Merck & Co Inc | 1- (AROMATIC OR HETEROAROMATICALLY SUBSTITUTED) -3- (HETEROAROMATICALLY SUBSTITUTED) -1,3-PROPANDIONS AND THEIR APPLICATIONS |
US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
PL364469A1 (en) | 2001-03-19 | 2004-12-13 | Ono Pharmaceutical Co, Ltd. | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient |
US7605168B2 (en) * | 2004-09-03 | 2009-10-20 | Plexxikon, Inc. | PDE4B inhibitors |
EP2220095B1 (en) * | 2007-11-15 | 2013-01-02 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
EP2220084B1 (en) * | 2007-11-16 | 2014-02-19 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
EP2220046B1 (en) | 2007-11-16 | 2014-06-18 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
US9132129B2 (en) * | 2010-11-15 | 2015-09-15 | Katholieke Universiteit Leuven | Antiviral compounds |
-
2012
- 2012-07-12 EP EP12814906.9A patent/EP2731436B1/en active Active
- 2012-07-12 US US13/547,199 patent/US8609653B2/en not_active Expired - Fee Related
- 2012-07-12 ES ES12814906.9T patent/ES2624984T3/es active Active
- 2012-07-12 JP JP2014520296A patent/JP6055468B2/ja not_active Expired - Fee Related
- 2012-07-12 WO PCT/US2012/046354 patent/WO2013012649A1/en active Application Filing
- 2012-07-13 UY UY0001034201A patent/UY34201A/es not_active Application Discontinuation
- 2012-07-13 AR ARP120102550A patent/AR087184A1/es not_active Application Discontinuation
- 2012-07-13 TW TW101125458A patent/TW201317237A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US8609653B2 (en) | 2013-12-17 |
EP2731436A1 (en) | 2014-05-21 |
WO2013012649A1 (en) | 2013-01-24 |
ES2624984T3 (es) | 2017-07-18 |
TW201317237A (zh) | 2013-05-01 |
JP2014522858A (ja) | 2014-09-08 |
AR087184A1 (es) | 2014-02-26 |
JP6055468B2 (ja) | 2016-12-27 |
US20130018049A1 (en) | 2013-01-17 |
EP2731436B1 (en) | 2017-03-08 |
EP2731436A4 (en) | 2015-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY34201A (es) | Compuestos de azaindol y métodos para el tratamiento de vih. | |
UY34648A (es) | Amidas como inhibidores de pim | |
UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
UY34472A (es) | Derivados modificados de 4-fenil-piridina | |
UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
UY34550A (es) | Bencilpirazoles sustituidos | |
UY34566A (es) | 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
UY34763A (es) | Inhibidores de la agregación plaquetaria | |
UY34593A (es) | Miméticos sintéticos de apelina para el tratamiento de falla cardiaca | |
UY34559A (es) | Inhibidores de bromodominios | |
UY33925A (es) | Inhibidores tricíclicos de quinasas | |
UY34820A (es) | Compuestos tipo pirrolo-pirrolidinona | |
UY34503A (es) | ?sal de bromhidrato de pridopidina? | |
UY34145A (es) | Compuestos inhibidores de metaloenzimas | |
UY33943A (es) | Derivados espirocíclicos de isoxazolina como agentes antiparasitarios. | |
UY34146A (es) | Compuestos inhibidores de metaloenzimas | |
UY34817A (es) | Tienopirimidinas | |
UY34374A (es) | Benzilindazoles sustituidos | |
UY34401A (es) | Métodos para el tratamiento de hcv | |
UY34402A (es) | Métodos para el tratamiento de hcv | |
UY34156A (es) | Compuestos inhibidores de metaloenzimas | |
UY34467A (es) | Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
UY34302A (es) | COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2- AMINA | |
TR201813877T4 (tr) | Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler. | |
UY34824A (es) | Nucleósidos de espirooxetano de uracilo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20201020 |